A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer

摘要: Background PTEN is a tumor suppressor frequently deleted in prostate cancer that may be useful prognostic biomarker. However, the association of loss with lethal disease has not been tested large, predominantly surgically treated cohort. Methods In Health Professionals Follow-up Study and Physicians' Study, we followed 1044 incident cases diagnosed between 1986 2009 for cancer-specific all-cause mortality. A genetically validated immunohistochemistry (IHC) assay was performed on tissue microarrays (TMAs). TMPRSS2:ERG status previously assessed subset by IHC ERG. Cox proportional hazards models adjusting age body mass index at diagnosis, Gleason grade, clinical or pathologic TNM stage were used to estimate hazard ratios (HRs) 95% confidence intervals (CIs) disease. All statistical tests two-sided. Results On average, men 11.7 years, during which there 81 events. Sixteen percent had complete all TMA cores 9% heterogeneous across cores. After adjustment clinical-pathologic variables, associated progression (HR = 1.8, CI 1.2 2.9). The (complete heterogeneous) only among ERG-negative 3.1, 1.7 5.7) but ERG-positive 1.2, 0.7 2.2) tumors. Conclusions independently increased risk progression, particularly ERG fusion-negative subgroup. These inexpensive assays stratification cancer.